A PILL sitting in many medicine cabinets may protect women against skin cancer.
Aspirin, a non-steroidal anti-inflammatory drug (NSAID), is known to protect against heart disease and colorectal cancer.
Now, data from 59,806 white women in the US supports the idea that it also protects against melanoma, the most dangerous type of skin cancer. Over a 12-year period, incidence of melanoma was 21 per cent lower in women taking high-dose aspirin at least twice a week than in people not taking NSAIDs regularly. In all, 115 of the 15,089 aspirin-takers developed melanoma, compared with 344 of 35,529 people (Cancer, DOI: 10.1002/cncr.27817).
A likely explanation is that aspirin dampens inflammation pathways that aggravate the spread of the cancer, says Jean Tang of the Stanford University School of Medicine in Palo Alto, California, who led the study.
"These findings need to be followed up to find out if there's a real effect," says Hazel Nunn, head of health information at Cancer Research UK. She adds that melanoma is largely preventable by protecting skin from sunburn.
This article appeared in print under the headline "Lowly aspirin fights deadly skin cancer"
If you would like to reuse any content from New Scientist, either in print or online, please contact the syndication department first for permission. New Scientist does not own rights to photos, but there are a variety of licensing options available for use of articles and graphics we own the copyright to.
Have your say
Only subscribers may leave comments on this article. Please log in.
Only personal subscribers may leave comments on this article
Subscribe now to comment.
All comments should respect the New Scientist House Rules. If you think a particular comment breaks these rules then please use the "Report" link in that comment to report it to us.
If you are having a technical problem posting a comment, please contact technical support.
pearl harbor Jacintha Saldanha Butch Jones thursday night football japan earthquake Star Trek Into Darkness Heisman watch
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন